Compare Biogen Inc (BIIB) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Lucid Group Inc — how do they compare? Biogen Inc trades at $193.38 (market cap $28.34B), while Lucid Group Inc trades at $5.48 (market cap $1.80B). The key difference: Biogen Inc is far larger — about 15.7× Lucid Group Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | LCID | |
|---|---|---|
Market Cap | $28.34B | $1.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $31.30 |
52-Week Low | $122.68 | $4.62 |
Enterprise Value | $30.62B | $4.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Lucid Group (LCID) trades at $5.51, down 0.72% amid significant volatility following bankruptcy rumors that the company denied on July 14, 2026. The stock shows bearish technical signals with negative financial metrics including a -239.81% net income margin and consistent earnings misses. Recent news highlights restructuring advisory engagement and multiple class-action lawsuits filed against the company, creating substantial investor uncertainty.
The outlook remains highly speculative with severe fundamental challenges including massive losses, negative cash flow, and declining revenue. While analyst consensus targets $10.50, representing 91% upside, the overwhelming hold/sell ratings and ongoing legal pressures suggest significant downside risk. Investment requires high risk tolerance given the company's financial distress and competitive EV market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
